DelveInsight’s “Renal Cell Carcinoma Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Renal Cell Carcinoma Treatment Landscape @ Renal Cell Carcinoma Pipeline Outlook
Key Takeaways from the Renal Cell Carcinoma Pipeline Report
- On May 29, 2026- Merck Sharp & Dohme LLC announced a phase 3 study is to learn if people who receive belzutifan and zanzalintinib live longer. A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
- On May 22, 2026- Oncorena AB initiated a phase I/II study evaluating the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal carcinoma. The study will include up to 75 patients and is conducted in 3 parts. The study will consist of 3 parts: Part A – an intra-patient dose escalation part, followed by a dose exposure (Part B), followed by a dose expansion (Part C).
- On May 22, 2026- Pfizer conducted a phase 1B/2 study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them
- On May 20, 2026- M.D. Anderson Cancer Center conducted a Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
- DelveInsight’s Renal Cell Carcinoma Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Renal Cell Carcinoma treatment.
- The leading Renal Cell Carcinoma Companies such as Telix Pharmaceuticals (Innovations) Pty Limited, Arcus Biosciences, Inc., Zhejiang Haichang Biotech Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Consorzio Oncotech, Beijing Biotech, Imbioray (Hangzhou) Biomedicine Co., Ltd., Oncorena AB, UTC Therapeutics Inc., Bristol-Myers Squibb, HiberCell, Inc., Xencor, Inc., Neomorph, Inc., Arcus Biosciences, Inc., Grit Biotechnology and others.
- Promising Renal Cell Carcinoma Therapies such as PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
Gain in-depth knowledge of key Renal Cell Carcinoma clinical trials, emerging drugs @ Renal Cell Carcinoma Clinical Trials Assessment
The Renal Cell Carcinoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Renal Cell Carcinoma Pipeline Report also highlights the unmet needs with respect to the Renal Cell Carcinoma.
Renal Cell Carcinoma Overview
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, originating from the lining of the renal tubules in the kidney. It accounts for approximately 85–90% of all kidney cancers. RCC often develops silently in the early stages, and many cases are discovered incidentally during imaging studies performed for other conditions. Common symptoms in advanced disease may include hematuria, flank pain, weight loss, fatigue, and a palpable abdominal mass. Several histological subtypes exist, with clear cell renal cell carcinoma being the most common.
Renal Cell Carcinoma Emerging Drugs Profile
- Casdatifan: Arcus Biosciences
Casdatifan (AB521) is an investigational oral small-molecule hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor being developed for clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. HIF-2α acts as a “master switch” that activates multiple genes under low-oxygen conditions, and in most patients with ccRCC this pathway remains abnormally activated because of VHL pathway abnormalities, promoting tumor growth and survival. Casdatifan is designed to provide deep and durable inhibition of the HIF-2α pathway, thereby blocking tumor proliferation, angiogenesis, treatment resistance, and cancer cell survival. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Renal Cell Carcinoma.
- BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.
BL-B01D1 is a first-in-class EGFR × HER3 bispecific antibody-drug conjugate (ADC) developed for the treatment of advanced solid tumors, including renal cell carcinoma and other urinary system tumors. The drug is designed to simultaneously target epidermal growth factor receptor (EGFR) and HER3 expressed on tumor cells and deliver a topoisomerase I inhibitor payload directly into cancer cells, thereby promoting selective tumor cell killing while limiting systemic toxicity. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Renal Cell Carcinoma.
- Orellanine: Oncorena AB
Orellanine is a first-in-class investigational therapy being developed for metastatic renal cell carcinoma, particularly clear-cell and papillary renal cell carcinoma. Orellanine is a toxin originally derived from mushrooms of the Cortinarius family and is being developed as an organ-specific chemotherapy for kidney cancer. The mechanism of action involves selective uptake into renal cancer cells through transporters highly expressed on kidney tumor cells, where it induces oxidative stress, disrupts mitochondrial function, down-regulates intracellular defense mechanisms, and ultimately triggers apoptosis and tumor cell death. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Renal Cell Carcinoma.
- XmAb819: Xencor, Inc.
XmAb819 is a first-in-class, tumor-targeted XmAb® 2+1 bispecific antibody being developed for patients with advanced clear cell renal cell carcinoma (ccRCC). The drug is designed to target ENPP3, an antigen highly expressed on kidney cancer cells, while simultaneously engaging CD3 on T cells to activate targeted immune-mediated killing of tumor cells. According to the company, the XmAb 2+1 format contains two ENPP3 binding domains and one CD3 binding domain, enabling selective binding to tumor cells with high antigen density while potentially sparing normal tissues. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Renal Cell Carcinoma.
Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Renal Cell Carcinoma Unmet Needs
The Renal Cell Carcinoma Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Renal Cell Carcinoma Treatment.
- Renal Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Renal Cell Carcinoma market.
Renal Cell Carcinoma Companies
Telix Pharmaceuticals (Innovations) Pty Limited, Arcus Biosciences, Inc., Zhejiang Haichang Biotech Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Consorzio Oncotech, Beijing Biotech, Imbioray (Hangzhou) Biomedicine Co., Ltd., Oncorena AB, UTC Therapeutics Inc., Bristol-Myers Squibb, HiberCell, Inc., Xencor, Inc., Neomorph, Inc., Arcus Biosciences, Inc., Grit Biotechnology and others
Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Renal Cell Carcinoma Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Transform your understanding of the Renal Cell Carcinoma Pipeline! @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Renal Cell Carcinoma Pipeline Report
- Coverage- Global
- Renal Cell Carcinoma Companies- Telix Pharmaceuticals (Innovations) Pty Limited, Arcus Biosciences, Inc., Zhejiang Haichang Biotech Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Consorzio Oncotech, Beijing Biotech, Imbioray (Hangzhou) Biomedicine Co., Ltd., Oncorena AB, UTC Therapeutics Inc., Bristol-Myers Squibb, HiberCell, Inc., Xencor, Inc., Neomorph, Inc., Arcus Biosciences, Inc., Grit Biotechnology and others.
- Renal Cell Carcinoma Therapies- PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
- Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Access the Full Renal Cell Carcinoma Pipeline Analysis Today! @ Renal Cell Carcinoma Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Renal Cell Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Renal Cell Carcinoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Casdatifan: Arcus Biosciences
- Mid Stage Products (Phase II)
- BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.
- Early Stage Products (Phase I)
- XmAb819: Xencor, Inc.
- Preclinical and Discovery Stage Products
- Inactive Products
- Renal Cell Carcinoma Key Companies
- Renal Cell Carcinoma Key Products
- Renal Cell Carcinoma – Unmet Needs
- Renal Cell Carcinoma – Market Drivers and Barriers
- Renal Cell Carcinoma – Future Perspectives and Conclusion
- Renal Cell Carcinoma Analyst Views
- Renal Cell Carcinoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/renal-cell-carcinoma-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/renal-cell-carcinoma-pipeline-insight